Treatment and post-treatment effects of α- versus β-receptor blockers on left ventricular structure and function in essential hypertension

American Heart Journal

Volumn 132, Issue 5, 1996, Pages 1004-1009

  Schobel, Hans P ^a   Langenfeld, Matthias ^a   Gatzka, Christoph ^a   Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; METOPROLOL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE; HEART RATE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029828988     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90013-7     Document Type: Article

References (29)

1. Messerli FH, Devereux RB. Left ventricular hypertrophy: good or evil? Am J Med 1983;75(Suppl 3A):1-3.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographic determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
4. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, et al. Value of echocardiographic measurement of left ventricular mass in predicting morbid events in hypertensive men. Ann Intern Med 1986;105:173-8.
5. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension [abstract]. Circulation 1990;82(Suppl III):29.
6. Motz W, Klepzig M, Stauer BE. Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol 1987:10(Suppl II):S148-52.
7. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of studies with high scientific quality. JAMA 1996;275:1507-13.
8. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
9. Östman-Smith I. Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. Clin Sci 1981;61:265-72.
10. Yamori Y, Tarazi RC, Ooshima A. Effect of β-receptor-blocking agents on cardiovascular structural changes in spontaneous and nor-adrenaline-induced hypertension in rats. Clin Sci 1980;59(Suppl):457S-60S.
11. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha adrenergic response. J Clin Invest 1983; 72:732-8.
12. Dahlöf B, Pennart K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. Am J Hypertens 1992;5:95-110.
13. Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med 1989;87:22-7.
14. Troy BL, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 1972;45:602-11.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb EJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;52:450-8.
16. DeSimone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994;23:1444-51.
17. Abi-Samra F, Fouad FM, Tarazi RC. Determinants of left ventricular hypertrophy and function in hypertensive patients: an echocardiographic study. Am J Med 1983;75(Suppl 3A):26-33.
18. McDonald IG, Feigenbaum H, Chang S. Analysis of left ventricular wall motion by reflected ultrasound. Circulation 1972;46:14-25.
19. Grossman W, Braunwald E, Mann T, McLaurin LP, Green LH. Contractile state of the left ventricle in man as evaluated from end-systolic and pressure volume relations. Circulation 1977;56:845-52.
20. Ikeda U, Tsuruya Y, Yaginuma T. Alphal-adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol 1991; 260:H953-6.
21. Zierhut W, Zimmer HG. Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989;65:1417-25.
22. Strauer BE, Bayer F, Brecht HM, Motz W. The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens 1985;3(Suppl 4):S39-44.
23. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Am J Cardiol 1982;49:795-801.
24. Laks MM, Morady F, Swan BA, Swan HJC. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 1973;64:75-9.
25. King BD, Sack D, Kichuk MR, Hintze TH. Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension 1987;9:582-90.
26. White WB, Schulman P, Karimeddini MK, Smith VE. Regression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprolol. Am Heart J 1989;117:145-50.
27. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontanously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 1989;7:83-90.
28. Adams MA, Bobik A, Korner PI. Enalapril induced regression of vascular structure in spontaneously hypertensive rats attenuates redevelopment of blood pressure when treatment is withdrawn [abstract]. J Hypertens 1989;7(Suppl 6):351.
29. Cuocolo A, Sax FL, Brush JE, Maron BJ, Bacharach SL, Bonow RO. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Circulation 1990;81:978-86.